Clinical Trial Update: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Merkel Cell Carcinoma
• Non-small Cell Lung Cancer
• Soft Tissue Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• BT-001
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Transgene | Conditions: Metastatic Cancer, Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: TERMINATED